Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
Unlike other nonnucleoside reverse transcriptase inhibitors, etravirine is only approved for use in treatment-experienced patients. In the DUET 1 and 2 trials, 1203 highly treatment-experienced patients were randomized to etravirine or placebo, in combination with darunavir/ritonavir and optimized b...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2014-01-01
|
| Series: | AIDS Research and Treatment |
| Online Access: | http://dx.doi.org/10.1155/2014/636584 |